AYTU BIOPHARMA, INC
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
7900 E. UNION AVENUE, DENVER, CO, 80237
Mailing Address
7900 E. UNION AVENUE, DENVER, CO, 80237
Phone
(720) 437-6580
Fiscal Year End
0630
EIN
470883144
Financial Overview
FY2025
-$15.84M
Net Income
$30.95M
Cash & Equivalents
$-2.16
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 3, 2026 | View on SEC |
| 8-K Current report of material events | February 3, 2026 | View on SEC |
| 8-K Current report of material events | January 20, 2026 | View on SEC |
| 8-K Current report of material events | December 10, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 14, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 13, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | November 12, 2025 | View on SEC |
Annual Reports
10-K
September 23, 2025
- Maintained ADHD drug supplies during industry-wide shortages
- Preparing to launch EXXUA, a new antidepressant, in 2025
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.